Little Green Pharma (ASX:LGP) EBIT: A$-1.09 Mil (TTM As of Mar. 2026)


What is Little Green Pharma EBIT?

Little Green Pharma ASX:LGP EBIT is A$-1.09 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Little Green Pharma's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was A$-0.40 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was A$-1.09 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Little Green Pharma's annualized ROC % for the quarter that ended in Mar. 2026 was 2.66%. Little Green Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1.07%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Little Green Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1.95%.

Little Green Pharma  (ASX:LGP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Little Green Pharma's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=3.072 * ( 1 - 22.01% )/( (91.092 + 89.1)/ 2 )
=2.3958528/90.096
=2.66 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=97.603 - 4.211 - ( 2.3 - max(0, 7.602 - 24.228+2.3))
=91.092

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=93.755 - 3.234 - ( 1.421 - max(0, 7.036 - 24.485+1.421))
=89.1

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Little Green Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.8/( ( (60.488 + max(15.493, 0)) + (56.464 + max(16.852, 0)) )/ 2 )
=-0.8/( ( 75.981 + 73.316 )/ 2 )
=-0.8/74.6485
=-1.07 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.26 + 15.506 + 3.162) - (4.211 + 0 + 2.224)
=15.493

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.645 + 13.901 + 3.08) - (3.234 + 0.124 + 2.416)
=16.852

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Little Green Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-1.089/55.752
=-1.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Little Green Pharma EBIT Related Terms

Little Green Pharma EBIT Historical Data

* Premium members only.

The historical data trend for Little Green Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Little Green Pharma EBIT Chart

Little Green Pharma Annual Data
Trend Jun19 Jun20 Jun21 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial 24.70 -7.63 -7.55 -4.47 -1.09

Little Green Pharma Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.77 -3.25 -1.22 -0.69 -0.40

ASX:LGP vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Little Green Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Little Green Pharma EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Little Green Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Little Green Pharma's EV-to-EBIT falls into.


Little Green Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-1.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of A$-1.09 Mil mean?
Little Green Pharma (ASX:LGP) has a EBIT of A$-1.09 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Little Green Pharma.
Is Little Green Pharma's EBIT too high?
Little Green Pharma's current EBIT is A$-1.09 Mil.
How does Little Green Pharma's EBIT compare to ZTS?
Little Green Pharma's EBIT of A$-1.09 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Little Green Pharma. Little Green Pharma's current EBIT is A$-1.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Little Green Pharma stock overvalued right now?
Based on GuruFocus' analysis, Little Green Pharma (ASX:LGP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.17, compared to a current price of A$0.06 — trading 62.4% below its estimated fair value. The current EBIT is A$-1.09 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Little Green Pharma (ASX:LGP), the current EBIT is A$-1.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Little Green Pharma Business Description

Address 13A Bedbrook Place, Shenton Park, West Perth, Perth, WA, AUS, 6008
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets. The Group is organized into two operating segments: Australia and Europe (cultivation, production and distribution of cannabis products to Australian and European customers).